Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy
Aggregate · 2026-04 · 7 (4)
DOI: 10.1002/agt2.70344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aggregate, online erschienen am 22.04.2026. Verfasst von Xiang Wang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) displays severe oxygen heterogeneity, which is regarded as a critical limitation to therapeutic efficacy. Herein, a targeted nanoplatform is engineered to overcome this barrier via a synergistic starvation/chemotherapy/Type I photodynamic therapy (PDT) strategy by co‐encapsulating glucose oxidase (GOx), tirapazamine (TPZ), and photosensitizer (sulfur‐substituted Nile Blue, ENBS) in galactose/biotin dual‐ligand‐modified liposomal nanoparticles (TGoE@BG‐Lipo). ENBS‐enabled Type I PDT provides oxygen‐independent photokilling, whereas GOx‐mediated glucose/oxygen depletion induces starvation and aggravates hypoxia to activate TPZ, together enabling efficient tumor eradication. TGoE@BG‐Lipo exhibits precise targeting with an 84‐fold higher uptake in HCC cells versus normal cells in a coculture model. In vitro, TGoE@BG‐Lipo/L generates O 2 −• through Type I PDT and produces robust reactive oxygen species (ROS) under both normoxic (3.1‐fold vs. untreated control) and hypoxic (2.1‐fold) conditions. This treatment induces both caspase‐3/GSDME‐dependent pyroptosis and immunogenic cell death (ICD) hallmarks upon irradiation. Thus, this synergistic treatment induces potent cell killing characterized by severe mitochondrial dysfunction (45.0% monomers) and achieves a tumor growth inhibition rate of 95.3 ± 1.1% in a hypoxic C5WN1 tumor model. Overall, this study presents a hypoxia‐adaptive nanoplatform for the precise eradication of oxygen‐heterogeneous HCC.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, X., Ma, Y., Li, H., Wang, L., Qin, M., Lou, R., Yin, J., Ming, W., Mao, Y., & Hu, J. (2026). Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy. Aggregate, 7(4). https://doi.org/10.1002/agt2.70344
Vancouver
Wang X, Ma Y, Li H, Wang L, Qin M, Lou R, et al. Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy. Aggregate. 2026;7(4). doi:10.1002/agt2.70344
BibTeX
@article{Wang2026,
author = {Wang, Xiang and Ma, Yihan and Li, Hengrui and Wang, Le and Qin, Miao and Lou, Rui and Yin, Jian and Ming, Wenbo and Mao, Yong and Hu, Jing},
title = {Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy},
journal = {Aggregate},
year = {2026},
volume = {7},
number = {4},
doi = {10.1002/agt2.70344}
}
EUVIMED